Aquired Resistance, EGFR TKIs, Non-small Cell Lung Cancer
Conditions
Brief summary
Patients with advanced non-small-cell lung cancer (NSCLC) harboring sensitive epithelial growth factor receptor (EGFR) mutations invariably develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Identification of actionable genetic mutations can be helpful for guiding the subsequent treatment. This study aimed to analyze the genetic profile of NSCLC harboring acquired resistance to the first-generation EGFR TKIs using next generation sequencing (NGS).
Interventions
OTHERGenetic: mutation profile
Sponsors
Zhejiang Cancer Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Histologically proven stage IIIB or IV non-small cell lung cancer * patients harboring sensitive EGFR mutations and received first-generation EGFR-TKIs who developed acquired drug resistance * patients who can provide pre-treatment (EGFR TKIs) tumor tissues * patients with tumor lesions to be re-biopsy after drug resistance * patients must sign an informed consent indicating that they are aware of the .investigational nature of the study in keeping with the policy of the hospital.
Exclusion criteria
* History of another malignancy except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix * patients with other systemic diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mutation profile | 10 days |
Countries
China
Contacts
Primary ContactYing Jin, MD
Outcome results
None listed